Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Cancer Epidemiol. 2013 Aug;37(4):385-9. doi: 10.1016/j.canep.2013.03.013. Epub 2013 Apr 22.
Whether rosiglitazone may increase bladder cancer risk has not been extensively investigated.
The reimbursement databases of all Taiwanese diabetic patients under oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 885,236 patients with type 2 diabetes were followed up for bladder cancer incidence till end of 2009. Incidences for ever-users, never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of time since starting rosiglitazone, duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression.
There were 102,926 ever-users and 782,310 never-users, respective numbers of incident bladder cancer 356 (0.35%) and 2753 (0.35%), and respective incidence 98.3 and 101.6 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) did not show significant association in unadjusted model [0.969 (0.867, 1.082)] and models adjusted for age and sex [0.983 (0.880, 1.098)] or all covariates [0.980 (0.870, 1.104)]. Neither the P values for the hazard ratios for the different categories of the dose-responsive parameters, nor their P-trends were significant.
Rosiglitazone does not increase the risk of bladder cancer.
罗格列酮是否会增加膀胱癌风险尚未得到广泛研究。
从 1996 年至 2009 年，从国家健康保险中检索了所有接受口服抗糖尿病药物或胰岛素治疗的台湾糖尿病患者的报销数据库。设定一个起始日期为 2006 年 1 月 1 日，共有 885236 名 2 型糖尿病患者接受随访，直至 2009 年底膀胱癌发病率。计算了既往使用者、从未使用者和罗格列酮暴露亚组（使用罗格列酮起始时间、治疗持续时间和累积剂量的三分位截断）的发生率，并通过 Cox 回归估计了风险比。
有 102926 名既往使用者和 782310 名从未使用者，分别有 356 例（0.35%）和 2753 例（0.35%）的膀胱癌新发病例，相应的发病率为每 100000 人年 98.3 和 101.6 例。在未调整模型[0.969（0.867，1.082）]和调整年龄和性别模型[0.983（0.880，1.098）]或所有协变量模型[0.980（0.870，1.104）]中，总体风险比（95%置信区间）均无显著相关性。剂量反应参数不同类别风险比的 P 值及其 P 趋势均无显著意义。
罗格列酮不会增加膀胱癌的风险。
